AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 163 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,042,569 | -15.8% | 42,124 | -3.7% | 0.00% | 0.0% |
| Q2 2023 | $1,238,688 | +18.3% | 43,739 | -4.1% | 0.00% | 0.0% |
| Q1 2023 | $1,047,501 | -22.4% | 45,603 | -5.1% | 0.00% | -25.0% |
| Q4 2022 | $1,349,300 | -4.0% | 48,052 | -3.3% | 0.00% | 0.0% |
| Q3 2022 | $1,405,000 | +19.0% | 49,697 | -6.7% | 0.00% | +33.3% |
| Q2 2022 | $1,181,000 | -49.2% | 53,259 | -33.3% | 0.00% | -40.0% |
| Q1 2022 | $2,326,000 | -11.4% | 79,900 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $2,626,000 | -28.8% | 79,900 | 0.0% | 0.01% | -37.5% |
| Q3 2021 | $3,687,000 | -16.3% | 79,900 | 0.0% | 0.01% | -11.1% |
| Q2 2021 | $4,403,000 | +995.3% | 79,900 | +925.7% | 0.01% | +800.0% |
| Q1 2021 | $402,000 | +17.2% | 7,790 | -1.5% | 0.00% | 0.0% |
| Q4 2020 | $343,000 | +19.1% | 7,905 | -4.0% | 0.00% | 0.0% |
| Q3 2020 | $288,000 | -33.3% | 8,235 | +2.0% | 0.00% | 0.0% |
| Q2 2020 | $432,000 | +49.5% | 8,075 | -0.9% | 0.00% | 0.0% |
| Q1 2020 | $289,000 | -29.2% | 8,145 | -4.7% | 0.00% | 0.0% |
| Q4 2019 | $408,000 | +72.2% | 8,545 | +17.0% | 0.00% | 0.0% |
| Q3 2019 | $237,000 | -35.4% | 7,305 | -0.7% | 0.00% | 0.0% |
| Q2 2019 | $367,000 | -42.3% | 7,360 | -21.9% | 0.00% | -50.0% |
| Q1 2019 | $636,000 | +42.0% | 9,426 | -2.9% | 0.00% | +100.0% |
| Q4 2018 | $448,000 | -40.2% | 9,706 | 0.0% | 0.00% | -50.0% |
| Q3 2018 | $749,000 | -10.4% | 9,706 | -2.3% | 0.00% | 0.0% |
| Q2 2018 | $836,000 | +3.2% | 9,931 | +0.3% | 0.00% | 0.0% |
| Q1 2018 | $810,000 | +65.6% | 9,904 | +15.7% | 0.00% | +100.0% |
| Q4 2017 | $489,000 | -13.3% | 8,559 | +1.3% | 0.00% | -50.0% |
| Q3 2017 | $564,000 | +32.4% | 8,449 | +2.1% | 0.00% | +100.0% |
| Q2 2017 | $426,000 | +17.7% | 8,274 | +33.6% | 0.00% | 0.0% |
| Q1 2017 | $362,000 | -49.2% | 6,194 | -63.8% | 0.00% | -66.7% |
| Q4 2016 | $713,000 | -31.7% | 17,096 | -13.5% | 0.00% | -25.0% |
| Q3 2016 | $1,044,000 | +34.9% | 19,770 | +7.0% | 0.00% | +33.3% |
| Q2 2016 | $774,000 | +6.6% | 18,470 | +3.4% | 0.00% | 0.0% |
| Q1 2016 | $726,000 | -40.6% | 17,870 | -5.1% | 0.00% | -40.0% |
| Q4 2015 | $1,223,000 | -10.2% | 18,840 | -2.3% | 0.01% | 0.0% |
| Q3 2015 | $1,362,000 | -38.1% | 19,290 | -2.6% | 0.01% | -37.5% |
| Q2 2015 | $2,201,000 | – | 19,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |